Global eradication of poliomyelitis: benefit-cost analysis.
A benefit-cost analysis of the Poliomyelitis Eradication Initiative was undertaken to facilitate national and international decision-making with regard to financial support. The base case examined the net costs and benefits during the period 1986-2040; the model assumed differential costs for oral poliovirus vaccine (OPV) and vaccine delivery in industrialized and developing countries, and ignored all benefits aside from reductions in direct costs for treatment and rehabilitation. The model showed that the "break-even" point at which benefits exceeded costs was the year 2007, with a saving of US$ 13 600 million by the year 2040. Sensitivity analyses revealed only small differences in the break-even point and in the dollars saved, when compared with the base case, even with large variations in the target age group for vaccination, the proportion of case-patients seeking medical attention, and the cost of vaccine delivery. The technical feasibility of global eradication is supported by the availability of an easily administered, inexpensive vaccine (OPV), the epidemiological characteristics of poliomyelitis, and the successful experience in the Americas with elimination of wild poliovirus infection. This model demonstrates that the Poliomyelitis Eradication Initiative is economically justified.
Bart
K J
KJ
Office of International Health, Department of Health, and Human Services (DHHS) Rockville, MD 20878, USA.
Foulds
J
J
Patriarca
P
P
D002675:Child, Preschool; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006801:Humans; D018803:Models, Economic; D011051:Poliomyelitis / Q000191:economics / Q000517:prevention & control*; D011055:Poliovirus Vaccine, Oral; D014611:Vaccination / Q000191:economics*
D011055:Poliovirus Vaccine, Oral